REPLIMUNE GROUP INC
NASDAQ: REPL (Replimune Group, Inc.)
Kemas kini terakhir: 16 jam lalu12.49
0.48 (4.00%)
| Penutupan Terdahulu | 12.01 |
| Buka | 11.78 |
| Jumlah Dagangan | 2,297,729 |
| Purata Dagangan (3B) | 820,656 |
| Modal Pasaran | 961,177,920 |
| Harga / Buku (P/B) | 2.24 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Feb 2025 - 10 Feb 2025 |
| EPS Cair (TTM) | -3.04 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.96% |
| Nisbah Semasa (MRQ) | 10.11 |
| Aliran Tunai Operasi (OCF TTM) | -181.10 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -113.40 M |
| Pulangan Atas Aset (ROA TTM) | -27.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Replimune Group, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.25 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.20% |
| % Dimiliki oleh Institusi | 92.17% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Braidwell Lp | 30 Sep 2024 | 3,070,837 |
| Omega Fund Management, Llc | 30 Sep 2024 | 2,461,319 |
| Boxer Capital, Llc | 30 Sep 2024 | 1,536,341 |
| Rtw Investments, Lp | 30 Sep 2024 | 1,133,787 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 19.00 (Jefferies, 52.12%) | Beli |
| Median | 17.50 (40.11%) | |
| Rendah | 17.00 (HC Wainwright & Co., 36.11%) | Beli |
| 17.00 (JP Morgan, 36.11%) | Beli | |
| Purata | 17.75 (42.11%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 13.53 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jefferies | 04 Dec 2024 | 19.00 (52.12%) | Beli | 13.17 |
| BMO Capital | 22 Nov 2024 | 18.00 (44.12%) | Beli | 14.93 |
| HC Wainwright & Co. | 22 Nov 2024 | 17.00 (36.11%) | Beli | 14.93 |
| 12 Nov 2024 | 17.00 (36.11%) | Beli | 12.19 | |
| JP Morgan | 24 Sep 2024 | 17.00 (36.11%) | Beli | 11.07 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |